Cannabis Law Report

SEPTEMBER 13, 2021

Positive data from this important study would significantly advance MYMD-1’s potential to become a blockbuster drug for inflammation and aging.”. The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. is the master regulator of inflammation, MYMD-1’s function as a TNF-?

Clinical Trials 52

Clinical Trials Pharmaceutical Research and Development Therapy 52

Cannabis Law Report

NOVEMBER 16, 2021

Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. Recruitment for the Phase 2 trial will begin immediately, and efficacy data is expected by the end of first quarter of 2022. “To BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

SMPL

MAY 26, 2020

Last year, the investment bank Cowen estimated that the U.S. CBD industry will be worth $16 billion by 2025. In 2020, CBD is available three ways: over the counter; at state-licensed marijuana dispensaries; or if you have certain forms of epilepsy, from GW Pharmaceuticals. On Instagram, #cbd is four times as common as #resist.

CBD 40

CBD Research and Development Pharmaceutical Seed-To-Sale 40

Cannabis Law Report

OCTOBER 17, 2019

Some of the potential health benefits associated with THC and CBD, with and without the high, respectively, include reducing chronic pain such as from migraines or cancer, alleviating anxiety, reducing inflammation, and helping treat conditions such as epilepsy, PTSD, and glaucoma. billion in 2025, according to Grandview Research.

Law 40

Law Seed-To-Sale Hemp Recreational 40